đź’ŠExclusive License for Zika Virus Therapy by NIH and Advocate Aurora
Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Development of Zika Virus Strains for Use in Oncolytic Therapy
Summary
The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Advocate Aurora Research Institute, located in Milwaukee, Wisconsin, to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice.
Agencies
- Health and Human Services Department
- National Institutes of Health
Business Impact
$$$ - High
The text outlines a prospective exclusive patent license for Zika virus strains, enabling Advocate Aurora Research Institute to develop oncolytic therapies. This presents a significant business opportunity for pharmaceutical and biotech companies focusing on cancer treatment and expands potential market avenues through sublicensing.